Price movement over the last 24 hours
Abeona Therapeutics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $54.9. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| ABEO | QCLN | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $68.47 |
52-Week Low | $4.17 | $34.04 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QCLN trades at $58.70, up 3.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed sentiment amid clean energy sector volatility, with support at $55 and resistance at $60. Recent news highlights policy risks from stalled US permits and geopolitical tensions affecting solar supply chains, while global investment in renewables continues to grow.
Outlook remains cautious due to regulatory headwinds and cost pressures, though long-term clean energy demand provides upside potential. Key risks include US-China trade policies and inflation-driven installation costs, with investor sentiment divided between near-term challenges and structural growth opportunities.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →